```html

Zoster Sinica (Herpes Zoster Oticus)

Overview

Zoster sinica, also known as herpes zoster oticus or Ramsay Hunt syndrome type 2, is a neurological disorder caused by the reactivation of the varicella‑zoster virus (VZV) in the facial nerve (cranial nerve VII) and often the vestibulocochlear nerve (cranial nerve VIII). The condition produces a painful rash around the ear or mouth, facial paralysis, and a range of auditory and vestibular symptoms.

• Who it affects: Adults of any age, but the risk rises sharply after age 50. Immunocompromised individuals (e.g., transplant recipients, HIV patients, those on chemotherapy) are disproportionately affected.
• Prevalence: In the United States, an estimated 5–12 cases per 100,000 persons develop Ramsay Hunt syndrome each year, accounting for roughly 8–12 % of all facial palsy cases. Worldwide, incidence mirrors that of herpes zoster—about 1 % of the population will develop shingles in a given year, and 1–2 % of those will have otic involvement (CDC, 2023).
• Why it matters: Prompt treatment reduces the risk of permanent facial weakness and hearing loss from ~40 % to < 15 %.

Symptoms

The clinical picture can evolve rapidly (often within 48 hours). The classic triad includes:

• Ear or facial rash: Vesicular lesions on the external ear, auditory canal, or around the mouth. The vesicles may crust over after 5‑7 days.
• Facial paralysis: One‑sided weakness ranging from mild droop to complete loss of movement in the muscles of facial expression.
• Auditory/vestibular symptoms: Sudden hearing loss, tinnitus, vertigo, or disequilibrium.

Additional symptoms

• Severe burning or stabbing ear pain, often preceding the rash.
• Dry eye or excessive tearing on the affected side.
• Altered taste (ageusia) on the anterior two‑thirds of the tongue.
• Difficulty chewing, speaking, or swallowing due to muscle weakness.
• Hyperacusis (increased sensitivity to sound) caused by stapedius muscle paralysis.
• Facial numbness or tingling (paresthesia).
• Post‑herpetic neuralgia – persistent neuropathic pain lasting > 90 days after rash resolution.

Causes and Risk Factors

Zoster sinica results from the same virus that causes chickenpox. After primary infection, VZV lies dormant in dorsal root and cranial nerve ganglia. Reactivation can be triggered by:

Primary cause

• Varicella‑zoster virus reactivation within the geniculate ganglion of the facial nerve.

Key risk factors

• Age ≥ 50 years – immune senescence reduces VZV surveillance.
• Immunosuppression – HIV/AIDS, organ transplantation, chemotherapy, long‑term corticosteroids.
• Stress or trauma – physical or emotional stress may weaken immunity.
• Recent head/ear trauma or surgery – may provoke local inflammation.
• Chronic medical conditions – diabetes, malignancy, or autoimmune diseases.
• Previous shingles episode – history of shingles elsewhere raises recurrence risk.

Diagnosis

Diagnosis is primarily clinical, supported by targeted tests when the presentation is atypical.

Clinical evaluation

• Detailed history of rash onset, ear pain, and facial weakness.
• Physical exam: inspection of vesicles, House‑Brackmann grading of facial palsy, otoscopic examination, and vestibular testing (e.g., Romberg, Dix‑Hallpike).

Laboratory / imaging studies

• Polymerase chain reaction (PCR) of vesicle fluid – Detects VZV DNA with > 95 % sensitivity.
• Direct fluorescent antibody (DFA) testing – Rapid but less widely available.
• Serology – VZV IgM/IgG can aid diagnosis but is less specific.
• Magnetic resonance imaging (MRI) of the brain and internal auditory canal – Performed when central nervous system involvement is suspected (e.g., meningitis, cerebellar involvement).
• Audiometry & vestibular testing – Baseline hearing assessment to document deficits and monitor recovery.

Treatment Options

Early intervention (ideally within 72 hours of symptom onset) markedly improves outcomes.

Antiviral therapy

• Acyclovir 800 mg five times daily for 7–10 days.
• Valacyclovir 1 g three times daily (preferred for better bioavailability).
• Famciclovir 500 mg three times daily.
• All regimens aim for a total of 10 days; dosage adjustment is required for renal impairment.

Corticosteroids

• Prednisone 60 mg daily, tapered over 10‑14 days, is commonly added to reduce inflammation and edema of the facial nerve.
• Meta‑analyses show combined antiviral + steroid therapy improves facial recovery rates by ~20 % compared with antivirals alone (Cochrane Review, 2022).

Pain management

• Acetaminophen or NSAIDs for mild‑to‑moderate pain.
• Gabapentin or pregabalin for neuropathic pain or post‑herpetic neuralgia.
• Topical lidocaine patches on the ear (if skin integrity allows).

Eye care (if facial palsy impairs eyelid closure)

• Artificial tears every 2‑4 hours.
• Lubricating ointment at night.
• Patch the eye or use an eye‑shield to prevent corneal drying and ulceration.

Physical therapy & facial rehabilitation

• Gentle facial muscle exercises 2–3 times daily.
• Biofeedback or electrical stimulation in selected cases.
• Referral to a speech‑language pathologist for swallowing or speech issues.

Surgical options (rare)

• Decompressive facial nerve surgery may be considered if there is no improvement after 3‑6 months and imaging shows significant nerve swelling.

Living with Zoster Sinica

Even with successful treatment, patients may experience residual deficits. Practical strategies can improve daily function.

Facial muscle care

• Practice “mirror exercises” – repeat smiling, frowning, and lip‑pursing while watching for symmetry.
• Massage the cheek gently to promote circulation (avoid vigorous rubbing).
• Apply warm compresses (not hot) for 10 minutes, 3‑4 times a day, to reduce stiffness.

Hearing & balance

• Use a hearing aid or bone‑conduction device if permanent hearing loss persists.
• Vestibular rehabilitation exercises (e.g., Brandt‑Daroff) can lessen vertigo.
• Avoid sudden head movements and high‑risk activities (e.g., driving) until dizziness resolves.

Eye protection

• Continue lubricating drops for at least 4–6 weeks after facial strength returns.
• Wear sunglasses outdoors to reduce photophobia and protect the cornea.

Pain & mental health

• Maintain a pain diary to track triggers and medication effectiveness.
• Consider cognitive‑behavioral therapy (CBT) if chronic pain interferes with sleep or mood.
• Support groups (online or local) can provide emotional reassurance.

Prevention

• Shingles vaccine – The recombinant zoster vaccine (Shingrix) is > 90 % effective at preventing herpes zoster and its complications. CDC recommends it for adults ≥ 50 years and for immunocompromised adults ≥ 19 years.
• Hand hygiene & avoiding close contact with individuals who have active chickenpox or shingles lesions, especially for pregnant women and immunocompromised persons.
• Maintain immune health – Balanced diet, regular exercise, adequate sleep, and management of chronic diseases (diabetes, hypertension) reduce reactivation risk.
• Prompt treatment of initial shingles – Early antiviral therapy for typical shingles lessens the chance of otic involvement.

Complications

If left untreated or inadequately managed, zoster sinica can lead to serious, sometimes permanent, sequelae:

• Permanent facial paralysis – May require surgical facial reanimation.
• Sensorineural hearing loss – May be severe and irreversible.
• Persistent vestibular dysfunction – Chronic disequilibrium and risk of falls.
• Post‑herpetic neuralgia – Chronic neuropathic pain lasting months to years.
• Corneal ulceration – From incomplete eye closure, can cause visual loss.
• Secondary bacterial infection of the vesicular rash.
• Intracranial complications – Rare meningitis, encephalitis, or cerebral vasculitis.

When to Seek Emergency Care

References

• Centers for Disease Control and Prevention. “Shingles (Herpes Zoster).” 2023. https://www.cdc.gov/shingles
• Mayo Clinic. “Ramsay Hunt syndrome.” Updated 2022. https://www.mayoclinic.org
• Cochrane Database of Systematic Reviews. “Antiviral agents for Ramsay Hunt syndrome.” 2022.
• World Health Organization. “Varicella‑zoster virus vaccines.” 2021. https://www.who.int
• Cleveland Clinic. “Facial nerve paralysis (Bell’s palsy & Ramsay Hunt).” 2023.
• NIH National Institute on Deafness and Other Communication Disorders. “Herpes Zoster Oticus.” 2022.

```